Phase 3 study of REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients.

Trial Profile

Phase 3 study of REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Pelareorep (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 20 Sep 2017 New trial record
    • 19 Sep 2017 According to an Oncolytics Biotech media release, data of this study will be used for to support a future Biologics License Application (BLA) submission.
    • 18 Sep 2017 According to an Oncolytics Biotech media release, company plans to include approximately four hundred patients with a pre-determined interim analysis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top